Loading…
Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy
Introduction The purpose of this retrospective study was to investigate the prognostic impact of neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune‐inflammation index (SII) in predicting outcomes for patients with locally advanced non‐sma...
Saved in:
| Published in: | Journal of medical imaging and radiation oncology 2022-02, Vol.66 (1), p.146-157 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3711-d9d742537c70a8bf34051125cfcfbfb6f78f30a27c70d1a3230a38827a6733b13 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3711-d9d742537c70a8bf34051125cfcfbfb6f78f30a27c70d1a3230a38827a6733b13 |
| container_end_page | 157 |
| container_issue | 1 |
| container_start_page | 146 |
| container_title | Journal of medical imaging and radiation oncology |
| container_volume | 66 |
| creator | Delikgoz Soykut, Ela Kemal, Yasemin Karacin, Cengiz Karaoglanoglu, Ozden Kurt, Mumin Aytac Arslan, Suheyla |
| description | Introduction
The purpose of this retrospective study was to investigate the prognostic impact of neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune‐inflammation index (SII) in predicting outcomes for patients with locally advanced non‐small‐cell lung cancer (NSCLC). The secondary endpoint was to evaluate the radiosensitivity in terms of response rate.
Methods
Newly diagnosed locally advanced NSCLC patients were enrolled. Immune inflammation biomarkers were calculated from baseline blood samples. Patients were stratified in two groups based on optimal cut‐off values for each biomarker. The associations between biomarkers and overall survival (OS), progression‐free survival (PFS), local regional recurrence‐free survival (LRRFS), and also response to radiotherapy were analysed.
Results
A total of 392 patients were included. Five‐year OS, PFS and LRRFS rates were 14.6%, 12.1%, and 13.4% respectively. Optimal cut‐off values for NLR, PLR, dNLR and SII were 3.07, 166, 2.02 and 817 respectively. Low NLR (HR 1.73, 95% CI 1.34–2.24, P |
| doi_str_mv | 10.1111/1754-9485.13341 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2580939640</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2580939640</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3711-d9d742537c70a8bf34051125cfcfbfb6f78f30a27c70d1a3230a38827a6733b13</originalsourceid><addsrcrecordid>eNqFkctu1DAUhiMEoqWwZocssWEzrW-Jk-WoKi1SJRBq15bj2B0XX4LtTDU7HoEn6UP1SXAmZRZs8ObYx58_HfmvqvcInqKyzhCr6aqjbX2KCKHoRXV86Lw87Bk7qt6kdA9hgxDtXldHhDYEM0SPq8dvMdz5kLKRwLhRyAyCLjs3eQWM11Y4J7IJHvQmOBF_qJhKH4xRDUZm4-9AmuLWbIUFwg8gisGEpHwy2WxN3u3ZIlA-J_Bg8gb44J9-_U5OWFuqVNYCOxWNFF6qCHJUIqthYeVGubBX5o2KYty9rV5pYZN691xPqtvPFzfnV6vrr5dfztfXK0kYQquhGxjFNWGSQdH2mlBYI4RrqaXudd9o1moCBZ7vByQILgfStpiJhhHSI3JSfVq8Yww_J5UydybNswqvwpQ4rlvYka6hsKAf_0HvwxR9mY7jBtMa4ha3hTpbKBlDSlFpPkZT_nPHEeRzlHwOi8_B8X2U5cWHZ-_UOzUc-L_ZFaBegAdj1e5_Pr7-vl7EfwCUeq6J</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624502828</pqid></control><display><type>article</type><title>Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Delikgoz Soykut, Ela ; Kemal, Yasemin ; Karacin, Cengiz ; Karaoglanoglu, Ozden ; Kurt, Mumin ; Aytac Arslan, Suheyla</creator><creatorcontrib>Delikgoz Soykut, Ela ; Kemal, Yasemin ; Karacin, Cengiz ; Karaoglanoglu, Ozden ; Kurt, Mumin ; Aytac Arslan, Suheyla</creatorcontrib><description>Introduction
The purpose of this retrospective study was to investigate the prognostic impact of neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune‐inflammation index (SII) in predicting outcomes for patients with locally advanced non‐small‐cell lung cancer (NSCLC). The secondary endpoint was to evaluate the radiosensitivity in terms of response rate.
Methods
Newly diagnosed locally advanced NSCLC patients were enrolled. Immune inflammation biomarkers were calculated from baseline blood samples. Patients were stratified in two groups based on optimal cut‐off values for each biomarker. The associations between biomarkers and overall survival (OS), progression‐free survival (PFS), local regional recurrence‐free survival (LRRFS), and also response to radiotherapy were analysed.
Results
A total of 392 patients were included. Five‐year OS, PFS and LRRFS rates were 14.6%, 12.1%, and 13.4% respectively. Optimal cut‐off values for NLR, PLR, dNLR and SII were 3.07, 166, 2.02 and 817 respectively. Low NLR (HR 1.73, 95% CI 1.34–2.24, P < 0.001), low PLR (HR 1.37, 95% CI 1.06–1.76, P = 0.013), low dNLR (HR 1.66, 95% CI 1.29–2.13, P < 0.001) and low SII (HR 1.63, 95% CI 1.18–2.04, P < 0.001) were independent prognostic factors for OS. Low NLR, PLR, dNLR and SII were also significant prognostic factors for PFS and LRRFS. Low NLR, low dNLR and low SII groups had better radiosensitivity than compared with high NLR, high dNLR and high SII groups (P = 0.001, P = 0.001 and P = 0.012).
Conclusion
NLR, PLR, dNLR and SII were independently associated with improved OS, PFS and LRRFS. Low NLR, dNLR and SII groups had better radiosensitivity. Immune inflammation biomarkers are promising prognostic predictors which can be obtained easily and inexpensively.</description><identifier>ISSN: 1754-9477</identifier><identifier>EISSN: 1754-9485</identifier><identifier>DOI: 10.1111/1754-9485.13341</identifier><identifier>PMID: 34632714</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Biomarkers ; Carcinoma, Non-Small-Cell Lung - radiotherapy ; Chemoradiotherapy ; Chemotherapy ; Humans ; immune inflammation biomarkers ; Inflammation ; Lung cancer ; Lung Neoplasms - radiotherapy ; Lymphocytes ; Medical prognosis ; Neutrophils ; non‐small‐cell lung cancer ; Prognosis ; prognostic factor ; Radiation therapy ; Radiation Tolerance ; radiosensitivity ; radiotherapy ; Retrospective Studies ; Survival</subject><ispartof>Journal of medical imaging and radiation oncology, 2022-02, Vol.66 (1), p.146-157</ispartof><rights>2021 Royal Australian and New Zealand College of Radiologists.</rights><rights>Copyright © 2022 The Royal Australian and New Zealand College of Radiologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3711-d9d742537c70a8bf34051125cfcfbfb6f78f30a27c70d1a3230a38827a6733b13</citedby><cites>FETCH-LOGICAL-c3711-d9d742537c70a8bf34051125cfcfbfb6f78f30a27c70d1a3230a38827a6733b13</cites><orcidid>0000-0003-1225-8458</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34632714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Delikgoz Soykut, Ela</creatorcontrib><creatorcontrib>Kemal, Yasemin</creatorcontrib><creatorcontrib>Karacin, Cengiz</creatorcontrib><creatorcontrib>Karaoglanoglu, Ozden</creatorcontrib><creatorcontrib>Kurt, Mumin</creatorcontrib><creatorcontrib>Aytac Arslan, Suheyla</creatorcontrib><title>Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy</title><title>Journal of medical imaging and radiation oncology</title><addtitle>J Med Imaging Radiat Oncol</addtitle><description>Introduction
The purpose of this retrospective study was to investigate the prognostic impact of neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune‐inflammation index (SII) in predicting outcomes for patients with locally advanced non‐small‐cell lung cancer (NSCLC). The secondary endpoint was to evaluate the radiosensitivity in terms of response rate.
Methods
Newly diagnosed locally advanced NSCLC patients were enrolled. Immune inflammation biomarkers were calculated from baseline blood samples. Patients were stratified in two groups based on optimal cut‐off values for each biomarker. The associations between biomarkers and overall survival (OS), progression‐free survival (PFS), local regional recurrence‐free survival (LRRFS), and also response to radiotherapy were analysed.
Results
A total of 392 patients were included. Five‐year OS, PFS and LRRFS rates were 14.6%, 12.1%, and 13.4% respectively. Optimal cut‐off values for NLR, PLR, dNLR and SII were 3.07, 166, 2.02 and 817 respectively. Low NLR (HR 1.73, 95% CI 1.34–2.24, P < 0.001), low PLR (HR 1.37, 95% CI 1.06–1.76, P = 0.013), low dNLR (HR 1.66, 95% CI 1.29–2.13, P < 0.001) and low SII (HR 1.63, 95% CI 1.18–2.04, P < 0.001) were independent prognostic factors for OS. Low NLR, PLR, dNLR and SII were also significant prognostic factors for PFS and LRRFS. Low NLR, low dNLR and low SII groups had better radiosensitivity than compared with high NLR, high dNLR and high SII groups (P = 0.001, P = 0.001 and P = 0.012).
Conclusion
NLR, PLR, dNLR and SII were independently associated with improved OS, PFS and LRRFS. Low NLR, dNLR and SII groups had better radiosensitivity. Immune inflammation biomarkers are promising prognostic predictors which can be obtained easily and inexpensively.</description><subject>Biomarkers</subject><subject>Carcinoma, Non-Small-Cell Lung - radiotherapy</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Humans</subject><subject>immune inflammation biomarkers</subject><subject>Inflammation</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Neutrophils</subject><subject>non‐small‐cell lung cancer</subject><subject>Prognosis</subject><subject>prognostic factor</subject><subject>Radiation therapy</subject><subject>Radiation Tolerance</subject><subject>radiosensitivity</subject><subject>radiotherapy</subject><subject>Retrospective Studies</subject><subject>Survival</subject><issn>1754-9477</issn><issn>1754-9485</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkctu1DAUhiMEoqWwZocssWEzrW-Jk-WoKi1SJRBq15bj2B0XX4LtTDU7HoEn6UP1SXAmZRZs8ObYx58_HfmvqvcInqKyzhCr6aqjbX2KCKHoRXV86Lw87Bk7qt6kdA9hgxDtXldHhDYEM0SPq8dvMdz5kLKRwLhRyAyCLjs3eQWM11Y4J7IJHvQmOBF_qJhKH4xRDUZm4-9AmuLWbIUFwg8gisGEpHwy2WxN3u3ZIlA-J_Bg8gb44J9-_U5OWFuqVNYCOxWNFF6qCHJUIqthYeVGubBX5o2KYty9rV5pYZN691xPqtvPFzfnV6vrr5dfztfXK0kYQquhGxjFNWGSQdH2mlBYI4RrqaXudd9o1moCBZ7vByQILgfStpiJhhHSI3JSfVq8Yww_J5UydybNswqvwpQ4rlvYka6hsKAf_0HvwxR9mY7jBtMa4ha3hTpbKBlDSlFpPkZT_nPHEeRzlHwOi8_B8X2U5cWHZ-_UOzUc-L_ZFaBegAdj1e5_Pr7-vl7EfwCUeq6J</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Delikgoz Soykut, Ela</creator><creator>Kemal, Yasemin</creator><creator>Karacin, Cengiz</creator><creator>Karaoglanoglu, Ozden</creator><creator>Kurt, Mumin</creator><creator>Aytac Arslan, Suheyla</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1225-8458</orcidid></search><sort><creationdate>202202</creationdate><title>Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy</title><author>Delikgoz Soykut, Ela ; Kemal, Yasemin ; Karacin, Cengiz ; Karaoglanoglu, Ozden ; Kurt, Mumin ; Aytac Arslan, Suheyla</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3711-d9d742537c70a8bf34051125cfcfbfb6f78f30a27c70d1a3230a38827a6733b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Carcinoma, Non-Small-Cell Lung - radiotherapy</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Humans</topic><topic>immune inflammation biomarkers</topic><topic>Inflammation</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Neutrophils</topic><topic>non‐small‐cell lung cancer</topic><topic>Prognosis</topic><topic>prognostic factor</topic><topic>Radiation therapy</topic><topic>Radiation Tolerance</topic><topic>radiosensitivity</topic><topic>radiotherapy</topic><topic>Retrospective Studies</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Delikgoz Soykut, Ela</creatorcontrib><creatorcontrib>Kemal, Yasemin</creatorcontrib><creatorcontrib>Karacin, Cengiz</creatorcontrib><creatorcontrib>Karaoglanoglu, Ozden</creatorcontrib><creatorcontrib>Kurt, Mumin</creatorcontrib><creatorcontrib>Aytac Arslan, Suheyla</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical imaging and radiation oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Delikgoz Soykut, Ela</au><au>Kemal, Yasemin</au><au>Karacin, Cengiz</au><au>Karaoglanoglu, Ozden</au><au>Kurt, Mumin</au><au>Aytac Arslan, Suheyla</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy</atitle><jtitle>Journal of medical imaging and radiation oncology</jtitle><addtitle>J Med Imaging Radiat Oncol</addtitle><date>2022-02</date><risdate>2022</risdate><volume>66</volume><issue>1</issue><spage>146</spage><epage>157</epage><pages>146-157</pages><issn>1754-9477</issn><eissn>1754-9485</eissn><abstract>Introduction
The purpose of this retrospective study was to investigate the prognostic impact of neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune‐inflammation index (SII) in predicting outcomes for patients with locally advanced non‐small‐cell lung cancer (NSCLC). The secondary endpoint was to evaluate the radiosensitivity in terms of response rate.
Methods
Newly diagnosed locally advanced NSCLC patients were enrolled. Immune inflammation biomarkers were calculated from baseline blood samples. Patients were stratified in two groups based on optimal cut‐off values for each biomarker. The associations between biomarkers and overall survival (OS), progression‐free survival (PFS), local regional recurrence‐free survival (LRRFS), and also response to radiotherapy were analysed.
Results
A total of 392 patients were included. Five‐year OS, PFS and LRRFS rates were 14.6%, 12.1%, and 13.4% respectively. Optimal cut‐off values for NLR, PLR, dNLR and SII were 3.07, 166, 2.02 and 817 respectively. Low NLR (HR 1.73, 95% CI 1.34–2.24, P < 0.001), low PLR (HR 1.37, 95% CI 1.06–1.76, P = 0.013), low dNLR (HR 1.66, 95% CI 1.29–2.13, P < 0.001) and low SII (HR 1.63, 95% CI 1.18–2.04, P < 0.001) were independent prognostic factors for OS. Low NLR, PLR, dNLR and SII were also significant prognostic factors for PFS and LRRFS. Low NLR, low dNLR and low SII groups had better radiosensitivity than compared with high NLR, high dNLR and high SII groups (P = 0.001, P = 0.001 and P = 0.012).
Conclusion
NLR, PLR, dNLR and SII were independently associated with improved OS, PFS and LRRFS. Low NLR, dNLR and SII groups had better radiosensitivity. Immune inflammation biomarkers are promising prognostic predictors which can be obtained easily and inexpensively.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34632714</pmid><doi>10.1111/1754-9485.13341</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-1225-8458</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1754-9477 |
| ispartof | Journal of medical imaging and radiation oncology, 2022-02, Vol.66 (1), p.146-157 |
| issn | 1754-9477 1754-9485 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2580939640 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Biomarkers Carcinoma, Non-Small-Cell Lung - radiotherapy Chemoradiotherapy Chemotherapy Humans immune inflammation biomarkers Inflammation Lung cancer Lung Neoplasms - radiotherapy Lymphocytes Medical prognosis Neutrophils non‐small‐cell lung cancer Prognosis prognostic factor Radiation therapy Radiation Tolerance radiosensitivity radiotherapy Retrospective Studies Survival |
| title | Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T07%3A17%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20impact%20of%20immune%20inflammation%20biomarkers%20in%20predicting%20survival%20and%20radiosensitivity%20in%20patients%20with%20non%E2%80%90small%E2%80%90cell%20lung%20cancer%20treated%20with%20chemoradiotherapy&rft.jtitle=Journal%20of%20medical%20imaging%20and%20radiation%20oncology&rft.au=Delikgoz%20Soykut,%20Ela&rft.date=2022-02&rft.volume=66&rft.issue=1&rft.spage=146&rft.epage=157&rft.pages=146-157&rft.issn=1754-9477&rft.eissn=1754-9485&rft_id=info:doi/10.1111/1754-9485.13341&rft_dat=%3Cproquest_cross%3E2580939640%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3711-d9d742537c70a8bf34051125cfcfbfb6f78f30a27c70d1a3230a38827a6733b13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2624502828&rft_id=info:pmid/34632714&rfr_iscdi=true |